Trials / Active Not Recruiting
Active Not RecruitingNCT05498896
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in Women With Triple-negative Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- Queen Mary University of London · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | IV infusion |
| DRUG | Ipatasertib | Oral |
| DRUG | Paclitaxel | IV infusion |
| DRUG | Doxorubicin | IV infusion |
| DRUG | Cyclophosphamide | IV infusion |
Timeline
- Start date
- 2018-12-19
- Primary completion
- 2021-01-29
- Completion
- 2026-01-30
- First posted
- 2022-08-12
- Last updated
- 2025-03-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05498896. Inclusion in this directory is not an endorsement.